Urgent Compliance Recovery Following Vendor Transition

Vendor transitions can expose hidden compliance risks, particularly when historical pharmacovigilance data has not been fully remediated. In Brazil, a regulatory inspection following a vendor change revealed critical legacy gaps in safety records generated prior to the transition, placing the national marketing authorisation at immediate risk. Time‑critical remediation was required under heightened regulatory scrutiny, with little margin for error.

Rapid local intervention, combined with structured central oversight, enabled clear ownership of corrective actions and direct engagement with national authorities. Inspection findings were prioritised, CAPAs reviewed, and targeted training deployed to address root causes rather than symptoms. Close coordination between local and global safety expertise ensured alignment with broader standards while stabilising the situation on the ground. As a result, critical findings were resolved within required timelines, regulatory confidence was restored, and the licence was successfully renewed.

The experience highlights how decisive governance, strong local leadership, and disciplined remediation can protect market continuity when inherited compliance issues surface unexpectedly. Read the full case study conducted by Prime Vigilance, a sister company of Ergormed Clinical Research, for practical insight into managing urgent compliance recovery scenarios.